Grifols takes $494M hit from Shanghai RAAS stake

Spanish plasma therapeutics company Grifols (NASDAQ:GRFS) on Tuesday reported an accounting adjustment of €457M ($494M) to account for a previously overstated value in its stake in Chinese blood ... ( read original story ...)